quantisnow
FeedTopReportsPricing
⌘K
Live feed
20:08:43·21d
INSIDERFiling
ImmunityBio Inc. logo

SEC Form 4 filed by Soon-Shiong Patrick

IBRX· ImmunityBio Inc.
Health Care
Original source

Companies

  • IBRX
    ImmunityBio Inc.
    Health Care

Recent analyst ratings

  • Mar 12UpdateBTIG Research$13.00
  • May 20UpdatePiper Sandler$5.00
  • Mar 6UpdateH.C. Wainwright$8.00
  • Jan 10UpdateBTIG Research$6.00
  • May 12UpdatePiper Sandler$4.00
  • Aug 3UpdateJefferies$8.00

Related

  • PR2d
    ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership
  • SEC14d
    ImmunityBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR14d
    ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
  • SEC17d
    ImmunityBio Inc. filed SEC Form 8-K: Regulation FD Disclosure
  • PR17d
    ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
  • SEC23d
    ImmunityBio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Regulation FD Disclosure
  • PR23d
    ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
  • PR28d
    ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022